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Abstract: Alzheimer’s disease is a neurodegenerative disorder that affects 
mostly the elderly. The main histopathological markers are the senile plaques 
formed by amyloid-β peptide (Aβ) aggregates that can perforate the plasma 
membrane of cells, increasing the intracellular calcium levels and releasing 
synaptic vesicles that finally lead to a delayed synaptic failure. Several 
membrane proteins and lipids interact with Aβ affecting its toxicity in neurons. 
Here, we focus on NMDA receptors (NMDARs) as proteins that could be 
modulating the association and neurotoxic perforation induced by Aβ on the 
plasma membrane. In fact, our results showed that decreasing NMDARs, 
using enzymatic or siRNA approaches, increased the association of Aβ to the 
neurons. Furthermore, overexpression of NMDARs also resulted in an 
enhanced association between NMDA and Aβ. Functionally, the reduction in 
membrane NMDARs augmented the process of membrane perforation. On the 
other hand, overexpressing NMDARs had a protective effect because Aβ was 
now unable to cause membrane perforation, suggesting a complex 
relationship between Aβ and NMDARs. Because previous studies have 
recognized that Aβ oligomers are able to increase membrane permeability and 
produce amyloid pores, the present study supports the conclusion that 
NMDARs play a critical protective role on Aβ actions in hippocampal neurons. 
These results could explain the lack of correlation between brain Aβ burden 
and clinically observed dementia. 
Keywords: Alzheimer’s disease, amyloid-beta, glutamate, glycine receptor, 
hippocampal neurons, membrane damage, membrane pore, NMDA receptor 
Introduction 
Alzheimer’s disease (AD) is the most prevalent 
neurodegenerative disorder in the elderly [1]. AD manifests 
progressively with cognitive and behavioral impairments [2] 
characterized by loss of memory and learning [3]. One of the major 
histopathological markers of AD are the senile plaques formed by 
amyloid-β peptide (Aβ) aggregates [4]. These Aβ aggregates produce 
a complex cascade of eventsthat finally lead to synaptic failure and 
neuronal death [5]. 
A common hypothesis used to explain the toxicity induced by Aβ 
is the formation of amyloid pores in the plasma membrane. Regarding 
this, several studies from our and other laboratories support the notion 
that membrane disruptions are induced by Aβ [6–13]. Furthermore, Aβ 
perforation allows the entry of small molecules and ions, such as 
calcium, into the cells [6, 7, 12]. This sustained calcium influx 
increases the release in synaptic vesicles, leading to a delayed 
synaptic failure produced by vesicle depletion [6–8]. 
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It is now believed that Aβ association and toxic actions at the 
membrane level can be affected by the lipid and protein composition 
[9, 12, 14–18].N-methyl-D-aspartate receptors (NMDARs) are exc-
itatory ligand gated ion channels that have been described as 
important for some of the toxic effects induced by Aβ, similar to that 
observed with other membrane proteins like cellular prion, mGluR5, 
nicotinic receptor, and AβPP [9, 19–25]. The glutamate NMDA receptor 
is a tetramer composed of different subunit combinations (NR1, NR2A-
D) allowing the influx of Na+ and Ca2 + ions into the neurons resulting 
in excitation [26, 27]. The relationship between AD and NMDARs is 
widely postulated [28, 29], but the mechanisms involving this 
relationship are not fully understood. 
One of the strongest evidence for the clinical relevance of such 
interactions between Aβ and NMDARs in AD is that the NMDA receptor 
antagonist, memantine, is used clinically in the treatment of AD [28]. 
In fact, other NMDAR antagonists, like (+)MK-801, or the removal of 
extracellular Ca2 +, reduced Aβ1–40-induced Ca2 + transients, NO 
production and neurotoxicity in cultured neuroblastoma cells [30]. 
Moreover, (+) MK-801 partially prevented the decrease in cell viability 
and the energy impairment induced by Aβ1–42 in HEK293 cells 
transiently expressing NR1/NR2A or NR1/NR2B subunits [29]. 
Regarding a potential interaction between Aβ and NMDAR, the 
data is controversial. While some authors indicate that the co-
immunoprecipitation of Aβ dodecameric oligomers with NR1 and NR2A 
is evidence for their interaction [31], others have failed to detect 
binding of Aβ1–42 to any known regulatory sites on glutamate receptors 
[28]. Furthermore, recent data indicates that such effects of Aβ1–42 on 
NMDA receptors may be due to its binding to postsynaptic anchoring 
proteins such as PSD-95 or other membrane proteins like prion [21, 
32, 33]. 
Here, in an attempt to clarify a potential role of NMDARs on Aβ1–
42-induced neurotoxicity, we examined the ability of the peptide to 
associate to and disrupt plasma membranes, something that has not 
been studied until now. The results indicate that NMDARs are an 
important factor controlling Aβ neurotoxicity. 
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Materials and Methods 
Primary cultures of rat hippocampal neurons 
Hippocampal neurons were obtained from 18-day pregnant 
Sprague-Dawley rats and maintained for10-14 days in vitro (DIV) as 
previously described [34]. All animals were handled in strict 
accordance with NIH guidelines and approved by the Ethics Committee 
of the Universidad de Concepción (Concepción, Chile). 
Peptide preparation and storage 
Human Aβ1–42 labeled with FAM (green fluorescence, Aβ-FAM) at 
its N-terminus, and unlabeled peptides were purchased from Anaspec 
(CA, USA). The preparation and storage were performed as previously 
reported by our lab [6]. Briefly, Aβ1–42 was dissolved in DMSO 
(10 mg/ml) and stored in aliquots at –20°C. To prepare Aβ oligomers 
(80 μM), aliquots of the peptide (250 μg in 25 μl of DMSO) were added 
to 700 μl of PBS (Gibco, USA) and vertically agitated (200 RPM at 
37°C) for 90 min and stored at 4°C until use. Aβ-FAM was dissolved in 
DMSO (4 mg/ml) and immediately stored in aliquots at –20°C. 
Transfection 
Neuronal transfection was performed using magnetofection with 
the reagent Neuromag as described by the protocol provided by the 
manufacturer (Oz Biosciences, France). To decrease the levels of 
NMDARs, siRNAs for NR1 and NR2B were co-transfected with GFP (2 
μg total) to visualize the transfected neurons. 
To increase the levels of NMDARs, HEK cells were transfected 
with the plasmids NR1, NR2B and GFP (2 μg total) using lipofectamine 
2000 (Invitrogen, USA) following the manufacturer’s instructions. The 
plasmids and siRNAs used in this study were previously described [35, 
36]. 
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Electrophysiology 
Electrophysiological recordings were carried out using the patch 
clamp technique as previously described [8, 37]. Briefly, culture media 
was changed for an external solution containing (in mM): 150 NaCl, 
5.4 KCl, 2.0 CaCl2, 1.0 MgCl2, 10 glucose and 10 HEPES (pH 7.4). The 
internal solution consisted of (in mM): 120 KCl, 2.0 MgCl2, 2 ATP-Na2, 
10 BAPTA, 0.5 GTP, 10 HEPES (pH 7.4). The holding potential was 
fixed at –60 mV and currents were acquired using a Digidata 1200 
board and the pClamp10 software (Axon Instruments, Inc.). Recording 
pipettes were pulled from borosilicate glass (WPI, Sarasota, FL) on a 
horizontal puller (Sutter Instruments, Novato, CA) having a 
resistancebetween 5 and 10 MΩ. Perforated recordings were obtained 
as previously described [6, 8]. Briefly, Aβ was added to the pipette 
internal solution and a 5 mV pulse was used to monitor the perforation 
in cell attached configuration. For evoked current recordings, the 
experiments were performed at room temperature (20–25°C) using a 
membrane potential of –60 mV. Data are given as mean±S.E.M. and 
were obtained from more than 5 experiments. Recordings were 
performed in the presence of 100 nM TTX (tetrodotoxin) to inhibit 
action potentials. 
Immunocytochemistry 
Experiments were performed as previously described [9]. The 
primary antibodies used for 16 hwere: anti-MAP2, 1 : 400 (Santa Cruz 
Biotechnology, CA, USA); and NR2B, 1 : 200 (Covance, USA). The 
secondary antibodies conjugated withFITC 
(ExMax/EmMax = 500/517 nm), Cy3 (ExMax/EmMax = 545/570 nm), or 
Cy5 (ExMax/EmMax= 649/670 nm) (1 : 400, Jackson ImmunoResearch 
Laboratories, USA) were incubated for 2 h for fluorescent staining. 
Finally, samples were mounted in fluorescent mounting medium 
(DAKO, CA, USA) and images were obtained using a Nikon Eclipse 
confocal microscope (Nikon, Japan). The immunoreactivity of the 
proteins was quantified at primary processes with ImageJ software 
(NIH). Fluorescent signal was quantified as relative units (RU) using a 
region of interest (ROI). 
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Western blots 
Equal amounts of proteins were separated on 10–12% SDS-
PAGE gels as previously described [7, 8]. Protein bands were 
transferred onto nitrocellulose membranes, blocked with 5% milk, and 
incubated with the primary antibody anti-NR2B (1 : 1000; Covance, 
USA) or α-tubulin (Sigma, USA). Immunoreactive bands were detected 
with secondary antibodies conjugated with HRP 1 : 5000 (Santa Cruz 
Biotechnology, CA, USA) and visualized with ECL Plus Western Blotting 
Detection System (PerkinElmer, MA, USA). 
Data analysis 
Non-lineal analysis was performed using Prism (Graph Pad). The 
analysis of the cluster size, number, and fluorescence intensity were 
performed using the ImageJ software package (NIH, USA) and using 
appropriate and similar intensity thresholds for cluster resolution. 
Membrane charge was analyzed by integrating the transient 
capacitative current after subtracting the pipette capacitance. The 
values are expressed as mean±SEM (standard error mean). Statistical 
differences were determined using Student’s t test or ANOVA. The 
experiments were performed in triplicate. 
Results 
We wanted to evaluate the potential role of NMDARs in the 
mechanism of Aβ1–42 association and perforation of the plasma 
membrane. Therefore, we used experimental protocols that could 
either decrease or increase the levels of NMDARs in the cell membrane 
before performing the assays. First, we used a mild enzymatic 
proteolytic digestion using trypsin (0.00025%, 30 min), a serine 
protease widely used to remove membrane proteins [38, 39], thus 
decreasing the levels of NMDARs in the membrane of hippocampal 
neurons as detected by immunocytochemistry against the NR2B 
subunit of the receptor (Fig. 1A). More detailed analyses of the 
immunofluorescence data showed that treatment of hippocampal 
neurons with trypsin decreased the NMDAR puncta number in primary 
neuronal processes (Fig. 1B). For instance, control values were 12±1.2 
punctas, and these values decreased to 6±1.10 punctas with the 
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treatment. This result is in agreement with western blot analyses that 
also showed a decrease of 60±12% in NMDAR total levels after the 
treatment as compared to control (Fig. 1 C,D). To evaluate if the 
treatment was actually reducing functional membrane NMDAR in the 
neurons treated with trypsin for 30 min, we performed 
electrophysiological recordings using patch clamp techniques. The 
neurons were stimulated with a large concentration of NMDA (100 μM) 
resulting in current amplitudes of several hundred pA. The results 
clearly showed a significant reduction in the amplitude of the NMDA-
evoked current in trypsin-treated neurons (approximately 20%) as 
compared to the control condition (Fig. 1E). An internal control using 
the NMDAR antagonist, D-AP5 (100 μM), showed that the NMDA-
evoked current was completely blocked by D-AP5, indicating that the 
evoked current was only mediated by NMDARs (Fig. 1E). As expected, 
the NMDA current density (pA/pF) was also significantly lowered in 
trypsin-treated neurons (4.4 ± 2 pA/pF)as compared to control cells 
(20 ± 2 pA/pF) (Fig. 1F). No differences were found in the values of 
membrane capacitance indicating that the treatment did not affect the 
size of the neurons (Fig. 1G). These data demonstrate that the use of 
a very low concentration of trypsin (0.00025%) is sufficient to 
decrease NMDAR levels in the neuronal membrane, making this 
experimental protocol a good tool for further assays which need 
decreased levels of this ion channel receptor. 
The next step was to evaluate the degree of association of 
oligomeric Aβ1–42 in control and trypsin treated neurons. Figure 2 
shows a confocal micrograph of NR2B (red) and MAP2 (blue) together 
with the fluorescent signal of Aβ (1 h incubation with Aβ1–42 coupled to 
FAM, a green fluorescent tag)in control and trypsin-treated cells. The 
overall analysis of this data shows that after treating the hippocampal 
neurons with trypsin, the NR2B signal was reduced and that of Aβ 
increased (Fig. 2A). The measurement of Aβ clusters in primary 
neurites corroborated the increase in Aβ-FAM association together with 
a decrease in NMDAR on trypsin-treated neurons (Fig. 2B). A more 
detailed analysis indicated that the Aβ-associated clusters were much 
larger after the treatment (Fig. 2C). In fact, trypsin-treated neurons 
resulted in an increase in the size of Aβ-FAM clusters together with the 
number of big clusters (Fig. 2C,D). 
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Furthermore, to characterize the role of NMDARs in Aβ 
association using more specific methodologies, we used siRNA for 
NMDAR subunits NR1 and NR2B to selectively decrease the NMDAR 
levels in these hippocampal neurons. Neuronal transfections for 48 h 
with siRNAs also reduced the amplitude of NMDA-evoked currents (100 
μM) in patch clamp recordings (Fig. 3A). For instance, the data show 
that treatment with the siRNA decreased the amplitude of the NMDA 
current from 720 ± 96 to 347 ± 63 pA (Fig. 3B), resulting in a 
reduction of approximately 48%. After confirming that the siRNA 
reduced the expression of membrane NMDARs, we incubated the 
neurons for 1 h with Aβ-FAM to assess the association to the neuronal 
membrane (Fig. 3C). The data obtained with immunocytochemistry 
showed that the siRNA-transfected neurons had an increase in Aβ-FAM 
association, incrementing the puncta number and the intensity of Aβ-
FAM signal in primary processes (Fig. 3D,E), similar to the results 
obtained in trypsin-treated neurons. 
Previous studies have shown that following Aβ association to the 
plasma membrane, a process of membrane damage begins that 
produces an increase in membrane current (perforation) and 
intracellular calcium levels which lead to a delayed synaptic failure [6–
8, 40]. Thus, the increase in membrane association of Aβ1–42 to 
neurons depleted of membrane NMDARs could result in an increase in 
membrane damage. To determine if this was actually occurring, we 
performed electrophysiological experiments using perforated patch 
clamp recordings, as previously described [6, 8, 41] (see methods), 
and found that Aβ1–42 increased the peak and charge of the 
capacitative current after 15 minutes of application in control neurons 
(Fig. 4A). The effect of Aβ1–42 on the amplitude of the capacitative 
current, on the other hand, developed much quicker in neurons 
previously treated with trypsin to reduce NMDAR (Fig. 4A). The 
treatment, however, did not have any effect on the holding current. 
The time course of Aβ1–42 effects on membrane charge in control and 
after trypsin shows that the treatment caused an increase in the 
perforation onset (Fig. 4B). Data show that the approximate t1/2 of Aβ 
effect on the perforation was 24 min in control conditions and reduced 
to 17 min with the treatment. Furthermore, the analysis of the time to 
acquire an open configuration (perforation) in control and trypsin-
treated neurons showed that the effect of Aβ1–42 was concentration-
dependent, with faster effects at higher concentrations (Fig. 4C). The 
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latter suggests that removal of membrane proteins, such as NMDARs, 
facilitates the membrane perforation induced by Aβ1–42. 
Next, we examined if increasing NMDARs in the cell membrane 
could have the opposite effect, thus increasing the association of Aβ 
and the consequent perforation of the membrane. Thus, we 
overexpressed and electrophysiologically characterizedthe NMDAR 
subunits NR1 and NR2B in HEK cells (Fig. 5A), and glycine receptor as 
a control (Fig. 5B), evaluating the association of Aβ-FAM after 1 h 
incubation (Fig. 5C). Data showed that the Aβ-FAM association 
increased in the cells that overexpressed NMDARs, resulting in a 
reduced distance between the Aβ-FAM clusters (Control 0.55 ± 0.03, 
NMDA-R 0.24 ± 0.01 pixels) and an increase in their size (Control 0.46 
± 0.05, NMDA-R 0.97 ± 0.04 μm) (Fig. 5B,C), which is similar to that 
observed when the levels of NMDARs were decreased (Figs. 2, 3). On 
the other hand, overexpression of another membrane protein that is 
associated to inhibitory transmission, the glycine receptor (GlyR), did 
not produce any change in Aβ-FAM association to the plasma 
membrane indicating that the effect was selective for NMDARs (Fig. 5). 
Thereafter, we evaluated the membrane perforation induced by Aβ1–
42in cells overexpressing NMDARs or GlyRs (Fig. 6A). The data 
obtained showed that NMDAR overexpression blocked the membrane 
perforation induced by Aβ1–42, while overexpression of GlyR was unable 
to affect the membrane charge transferred (Control 12.3 ± 5.3, Aβ 
155.3 ± 14.3, NMDAR 25.4 ± 4.8, GlyRα1 135.9 ± 13.8 fC) (Fig. 6B). 
As a positive control for membrane perforation, we used a small 
peptide constructed with the native sequence of Aβ11–17 that includes 
the two histidine residues 13 and 14 (EVHHQKL) [42] which blocked 
the perforation of the membrane induced by Aβ (Fig. 6B) [6, 41, 42]. 
The latter suggests that NMDAR presence in the membrane of the cells 
increases Aβ association but interferes with the perforation induced by 
the peptide. 
Discussion 
The presence of a direct or indirect interaction between Aβ and 
NMDARs is still under discussion, however, the role of NMDARs in AD is 
becoming more recognized [28]. Previous studies, for example, are 
focused on the use of NMDAR antagonists, like memantine or (+) MK-
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801 as AD treatments [29, 30]. In fact, memantine is one of the few 
FDA approved drugs for AD [43, 44]. 
In the present study, we characterized a largely unexplored area 
of the NMDAR relationship with Aβ regarding membrane association 
and subsequent perforation and that might have clinical implications. 
The original idea was to evaluate if the association of Aβ to the plasma 
membrane was affected by altering the levels of functional NMDARs, 
thus, cells were treated with trypsin to reduce receptor levels, or 
transfected with plasmids containing NMDAR subunits to increase the 
receptor levels. Interestingly, both treatments resulted in higher 
association of Aβ to the cells, suggesting a more complex role of 
NMDARs than expected. A simple way of explaining these results of Aβ 
association is what we call the “forest effect”, where the membrane 
proteins can be likened to trees covering the ground (lipids) (Fig. 7). 
Thus, decreasing the level of NMDARs, suggested to be important for 
the interaction of Aβ with the neuronal membrane [21, 31], might be 
facilitating its association to lipids previously not accessible, resulting 
in enhanced clustering (Figs. 2 and 3). On the other hand, the increase 
in Aβ association after the overexpression of NMDARs might be due to 
enhanced direct or indirect interactions with these excitatory 
receptors. In agreement, it is now believed that Aβ has promiscuous 
membrane interactions associating to cellular prion, nicotinic 
receptors, AβPP, and lipids like GM1 and cholesterol, thus affecting Aβ 
clustering [9, 15, 17, 19–25]. Therefore, the increased Aβ association 
after overexpression of NMDARs could be explained by the formation 
of Aβ/NMDAR complexes [20, 31]. Interestingly, this effect was 
specific for NMDARs since overexpression of GlyRs did not affect Aβ 
association to the membrane. This differential effect might be relevant 
for the disease because GlyRs, unlike NMDARs, are inhibitory proteins 
that are mainly expressed in spinal cord neurons [45, 46], which are 
believed to be largely unaffected by the disease. 
Interestingly, although decreasing or increasing NMDARs 
resulted in similar increases in Aβ association to the membrane 
(clustering), our data showed that the functional impact of altering the 
levels of NMDARs in the membrane was quite different. For instance, 
decreasing NMDARs resulted in an accelerated rate of brain membrane 
damage revealed as an increase in membrane current in the presence 
of Aβ. This is remarkable because it demonstrates differences on the 
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impact that Aβ association has on the plasma membrane. One 
plausible explanation is that the fine-tuning of Aβ interaction with 
membrane lipids and proteins affects its capacity to form amyloid 
pores. Thus, a membrane devoid of some types of proteins (i.e., 
NMDARs) might be more sensitive to Aβ-induced damage. It was 
reported that increasing protein levels in the membrane produced a 
reduction on its fluidity [47], thus our results might also be explained 
by a reduced level of membrane fluidity. Nevertheless, lipid rafts can 
also regulate Aβ association to the membrane [15, 17, 18]. For 
instance, cholesterol in lipid rafts can affect Aβ association and 
membrane damage by decreasing membrane fluidity as a consequence 
of reduced phospholipid movement in the bilayer [17, 48]. 
On the other hand, we found that the decrease in NMDAR levels 
by siRNAs or trypsin also increased Aβ association. In parallel, the 
perforation of the membrane was faster when compared to control 
cells (Fig. 5). We believe that by decreasing the levels of NMDARs, Aβ 
associates preferentially to membrane lipids facilitating the process of 
perforation [15, 16, 49]. For example, it is believed that GM1 mediates 
Aβ association, seeding, fibrillogenesis and membrane disruption [15, 
49]. These results could very well explain why some people with high 
levels of Aβ in the brain do not show dementia and vice versa. In other 
words, some proteins might be buffering the levels of toxic Aβ [50]. 
In conclusion, our data support the role of NMDARs as an 
important mediator for Aβ association and damage/perforation in the 
plasma memb-rane, actively participating in the membrane toxicity 
induced by Aβ. These results could explain the lack of correlation 
between brain Aβ burden and clinically observed dementia. 
Acknowledgments 
We thank Lauren Aguayo for revising the manuscript and for technical 
assistance, and Cecilia González for graphic design. This work was supported 
by FONDECYT grant N° 1140473. EF is a CONICYT fellow. 
Authors’ disclosures available online (http://j-alz.com/manuscript-
disclosures/16-0170r1). 
  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Alzheimer’s Disease, Vol 53, No. 1 (2016): pg. 197-207. DOI. This article is © IOS Press and permission has been 
granted for this version to appear in e-Publications@Marquette. IOS Press does not grant permission for this article to be 
further copied/distributed or hosted elsewhere without the express permission from IOS Press. 
12 
 
References 
[1]  Evans DA , Funkenstein HH , Albert MS , Scherr PA , Cook NR , Chown 
MJ , Hebert LE , Hennekens CH , Taylor JO ((1989) ) Prevalence of 
Alzheimer’s disease in a community population of older persons. Higher 
than previously reported. JAMA 262:, 2551–2556. 
[2]  Faber-Langendoen K , Morris JC , Knesevich JW , LaBarge E , Miller JP , 
Berg L ((1988) ) Aphasia in senile dementia of the Alzheimer type. Ann 
Neurol 23:, 365–370. 
[3]  Spires TL , Hyman BT ((2005) ) Transgenic models of Alzheimer’s 
disease: Learning from animals. NeuroRx 2:, 423–437. 
[4]  Ittner LM , Gotz J ((2011) ) Amyloid-beta and tau–a toxic pas de deux 
in Alzheimer’s disease. Nat Rev Neurosci 12:, 65–72. 
[5]  Selkoe DJ ((2002) ) Alzheimer’s disease is a synaptic failure. Science 
298:, 789–791. 
[6]  Sepulveda FJ , Parodi J , Peoples RW , Opazo C , Aguayo LG ((2010) ) 
Synaptotoxicity of Alzheimer beta amyloid can be explained by its 
membrane perforating property. PLoS One 5:, e11820. 
[7]  Parodi J , Sepulveda FJ , Roa J , Opazo C , Inestrosa NC , Aguayo LG 
((2009) ) Beta-amyloid causes depletion of synaptic vesicles leading to 
neurotransmission failure. J Biol Chem 285:, 2506–2514. 
[8]  Peters C , Fernandez-Perez EJ , Burgos CF , Espinoza MP , Castillo C , 
Urrutia JC , Streltsov VA , Opazo C , Aguayo LG ((2013) ) Inhibition of 
amyloid beta-induced synaptotoxicity by a pentapeptide derived from 
the glycine zipper region of the neurotoxic peptide. Neurobiol Aging 
34:, 2805–2814. 
[9]  Peters C , Espinoza MP , Gallegos S , Opazo C , Aguayo LG ((2015) ) 
Alzheimer’s Abeta interacts with cellular prion protein inducing neuronal 
membrane damage and synaptotoxicity. Neurobiol Aging 36:, 1369–
1377. 
[10]  Arispe N , Rojas E , Pollard HB ((1993) ) Alzheimer disease amyloid 
beta protein forms calcium channels in bilayer membranes: Blockade 
by tromethamine and aluminum. Proc Natl Acad Sci U S A 90:, 567–
571. 
[11]  Arispe N , Pollard HB , Rojas E ((1996) ) Zn2+ interaction with 
Alzheimer amyloid beta protein calcium channels. Proc Natl Acad Sci U 
S A 93:, 1710–1715. 
[12]  Kawahara M , Ohtsuka I , Yokoyama S , Kato-Negishi M , Sadakane Y 
((2011) ) Membrane incorporation, channel formation, and disruption 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Alzheimer’s Disease, Vol 53, No. 1 (2016): pg. 197-207. DOI. This article is © IOS Press and permission has been 
granted for this version to appear in e-Publications@Marquette. IOS Press does not grant permission for this article to be 
further copied/distributed or hosted elsewhere without the express permission from IOS Press. 
13 
 
of calcium homeostasis by Alzheimer’s beta-amyloid protein. Int J 
Alzheimers Dis 2011:, 304583. 
[13]  Quist A , Doudevski I , Lin H , Azimova R , Ng D , Frangione B , Kagan 
B , Ghiso J , Lal R ((2005) ) Amyloid ion channels: A common structural 
link for protein-misfolding disease. Proc Natl Acad Sci U S A 102:, 
10427–10432. 
[14]  Lauren J , Gimbel DA , Nygaard HB , Gilbert JW , Strittmatter SM 
((2009) ) Cellular prion protein mediates impairment of synaptic 
plasticity by amyloid-beta oligomers. Nature 457:, 1128–1132. 
[15]  Kakio A , Nishimoto SI , Yanagisawa K , Kozutsumi Y , Matsuzaki K 
((2001) ) Cholesterol-dependent formation of GM1 ganglioside-bound 
amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J Biol 
Chem 276:, 24985–24990. 
[16]  Yanagisawa K , Odaka A , Suzuki N , Ihara Y ((1995) ) GM1 
ganglioside-bound amyloid beta-protein (A beta): A possible form of 
preamyloid in Alzheimer’s disease. Nat Med 1:, 1062–1066. 
[17]  Di Scala C , Troadec J-D , Lelièvre C , Garmy N , Fantini J , Chahinian H 
((2014) ) Mechanism of cholesterol-assisted oligomeric channel 
formation by a short Alzheimerβ-amyloid peptide. J Neurochem 128:, 
186–195. 
[18]  Arispe N , Doh M ((2002) ) Plasma membrane cholesterol controls the 
cytotoxicity of Alzheimer’s disease AbetaP (1-40) and (1-42) peptides. 
FASEB J 16:, 1526–1536. 
[19]  Lorenzo A , Yuan M , Zhang Z , Paganetti PA , Sturchler-Pierrat C , 
Staufenbiel M , Mautino J , Vigo FS , Sommer B , Yankner BA ((2000) ) 
Amyloid beta interacts with the amyloid precursor protein: A potential 
toxic mechanism in Alzheimer’s disease. Nat Neurosci 3:, 460–464. 
[20]  Um Ji W , Kaufman Adam C , Kostylev M , Heiss Jacqueline K , Stagi 
M , Takahashi H , Kerrisk Meghan E , Vortmeyer A , Wisniewski T , 
Koleske Anthony J , Gunther Erik C , Nygaard Haakon B , Strittmatter 
Stephen M ((2013) ) Metabotropic glutamate receptor 5 is a coreceptor 
for Alzheimer Aβ oligomer bound to cellular prion protein. Neuron 79:, 
887–902. 
[21]  Um JW , Nygaard HB , Heiss JK , Kostylev MA , Stagi M , Vortmeyer A , 
Wisniewski T , Gunther EC , Strittmatter SM ((2012) ) Alzheimer 
amyloid-beta oligomer bound to postsynaptic prion protein activates 
Fyn to impair neurons. Nat Neurosci 15:, 1227–1235. 
[22]  Fu W ((2003) ) β-amyloid peptide activates non- 7 nicotinic 
acetylcholine receptors in rat basal forebrain neurons. J Neurophysiol 
90:, 3130–3136. 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Alzheimer’s Disease, Vol 53, No. 1 (2016): pg. 197-207. DOI. This article is © IOS Press and permission has been 
granted for this version to appear in e-Publications@Marquette. IOS Press does not grant permission for this article to be 
further copied/distributed or hosted elsewhere without the express permission from IOS Press. 
14 
 
[23]  Cullen WK , Wu J , Anwyl R , Rowan MJ ((1996) ) β-Amyloid produces a 
delayed NMDA receptor-dependent reduction in synaptic transmission 
in rat hippocampus. Neuroreport 8:, 87–92. 
[24]  He Y , Cui J , Lee JCM , Ding S , Chalimoniuk M , Simonyi A , Sun AY , 
Gu Z , Weisman GA , Gibson Wood W , Sun GY ((2011) ) Prolonged 
exposure of cortical neurons to oligomeric amyloid-β impairs NMDA 
receptor function via NADPH oxidase-mediated ROS production: 
Protective effect of green tea (–)-epigallocatechin-3-gallate. ASN Neuro 
3:, 13–24. 
[25]  Li S , Jin M , Koeglsperger T , Shepardson NE , Shankar GM , Selkoe DJ 
((2011) ) Soluble Aβ oligomers inhibit long-term potentiation through a 
mechanism involving excessive activation of extrasynaptic NR2B-
containing NMDA receptors. J Neurosci 31:, 6627–6638. 
[26]  Chaffey H , Chazot PL ((2008) ) NMDA receptor subtypes: Structure, 
function and therapeutics. Curr Anaesth Crit Care 19:, 183–201. 
[27]  Regehr WG , Tank DW ((1990) ) Postsynaptic NMDA receptor-mediated 
calcium accumulation in hippocampal CA1 pyramidal cell dendrites. 
Nature 345:, 807–810. 
[28]  Danysz W , Parsons CG ((2012) ) Alzheimer’s disease,β-amyloid, 
glutamate, NMDA receptors and memantine - searching for the 
connections. Br J Pharmacol 167:, 324–352. 
[29]  Domingues A , Almeida S , da Cruz e Silva EF , Oliveira CR , Rego AC 
((2007) ) Toxicity of beta-amyloid in HEK293 cells expressing 
NR1/NR2A or NR1/NR2B N-methyl-D-aspartate receptor subunits. 
Neurochem Int 50:, 872–880. 
[30]  Le WD , Colom LV , Xie WJ , Smith RG , Alexianu M , Appel SH 
((1995) ) Cell death induced by beta-amyloid 1-40 in MES 23.5 hybrid 
clone: The role of nitric oxide and NMDA-gated channel activation 
leading to apoptosis. Brain Res 686:, 49–60. 
[31]  Venkitaramani DV , Chin J , Netzer WJ , Gouras GK , Lesne S , Malinow 
R , Lombroso PJ ((2007) ) Beta-amyloid modulation of synaptic 
transmission and plasticity. J Neurosci 27:, 11832–11837. 
[32]  De Felice FG , Velasco PT , Lambert MP , Viola K , Fernandez SJ , 
Ferreira ST , Klein WL ((2007) ) Abeta oligomers induce neuronal 
oxidative stress through an N-methyl-D-aspartate receptor-dependent 
mechanism that is blocked by the Alzheimer drug memantine. J Biol 
Chem 282:, 11590–11601. 
[33]  Lacor PN , Buniel MC , Furlow PW , Clemente AS , Velasco PT , Wood 
M , Viola KL , Klein WL ((2007) ) Abeta oligomer-induced aberrations in 
synapse composition, shape, and density provide a molecular basis for 
loss of connectivity in Alzheimer’s disease. J Neurosci 27:, 796–807. 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Alzheimer’s Disease, Vol 53, No. 1 (2016): pg. 197-207. DOI. This article is © IOS Press and permission has been 
granted for this version to appear in e-Publications@Marquette. IOS Press does not grant permission for this article to be 
further copied/distributed or hosted elsewhere without the express permission from IOS Press. 
15 
 
[34]  Aguayo LG , Pancetti FC ((1994) ) Ethanol modulation of the gamma-
aminobutyric acidA- and glycine-activated Cl- current in cultured 
mouse neurons. J Pharmacol Exp Ther 270:, 61–69. 
[35]  Bustos FJ , Varela-Nallar L , Campos M , Henriquez B , Phillips M , 
Opazo C , Aguayo LG , Montecino M , Constantine-Paton M , Inestrosa 
NC , van Zundert B ((2014) ) PSD95 suppresses dendritic arbor 
development in mature hippocampal neurons by occluding the 
clustering of NR2B-NMDA receptors. PLoS One 9:, e94037. 
[36]  Sepulveda FJ , Bustos FJ , Inostroza E , Zuniga FA , Neve RL , 
Montecino M , van Zundert B ((2010) ) Differential roles of NMDA 
Receptor Subtypes NR2A and NR2B in dendritic branch development 
and requirement of RasGRF1. J Neurophysiol 103:, 1758–1770. 
[37]  Peters C , Munoz B , Sepulveda FJ , Urrutia J , Quiroz M , Luza S , De 
Ferrari GV , Aguayo LG , Opazo C ((2011) ) Biphasic effects of copper 
on neurotransmission in rat hippocampal neurons. J Neurochem 119:, 
78–88. 
[38]  Lepke S , Passow H ((1976) ) Effects of incorporated trypsin on anion 
exchange and membrane proteins in human red blood cell ghosts. 
Biochim Biophys Acta 455:, 353–370. 
[39]  Molloy MP , Herbert BR , Walsh BJ , Tyler MI , Traini M , Sanchez JC , 
Hochstrasser DF , Williams KL , Gooley AA ((1998) ) Extraction of 
membrane proteins by differential solubilization for separation using 
two-dimensional gel electrophoresis. Electrophoresis 19:, 837–844. 
[40]  Peters C , Espinoza MP , Gallegos S , Opazo C , Aguayo LG ((2015) ) 
Alzheimer’s Aβ interacts with cellular prion protein inducing neuronal 
membrane damage and synaptotoxicity. Neurobiol Aging 36:, 1369–
1377. 
[41]  Sepúlveda FJ , Fierro H , Fernandez E , Castillo C , Peoples RW , Opazo 
C , Aguayo LG ((2014) ) Nature of the neurotoxic membrane actions of 
amyloid-β on hippocampal neurons in Alzheimer’s disease. Neurobiol 
Aging 35:, 472–481. 
[42]  Diaz JC , Linnehan J , Pollard H , Arispe N ((2006) ) Histidines 13 and 
14 in the Abeta sequence are targets for inhibition of Alzheimer’s 
disease Abeta ion channel and cytotoxicity. Biol Res 39:, 447–460. 
[43]  Reisberg B , Doody R , Stoffler A , Schmitt F , Ferris S , Mobius HJ 
((2006) ) A 24-week open-label extension study of memantine in 
moderate to severe Alzheimer disease. Arch Neurol 63:, 49–54. 
[44]  Doody RS , Tariot PN , Pfeiffer E , Olin JT , Graham SM ((2007) ) Meta-
analysis of six-month memantine trials in Alzheimer’s disease. 
Alzheimers Dement 3:, 7–17. 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Alzheimer’s Disease, Vol 53, No. 1 (2016): pg. 197-207. DOI. This article is © IOS Press and permission has been 
granted for this version to appear in e-Publications@Marquette. IOS Press does not grant permission for this article to be 
further copied/distributed or hosted elsewhere without the express permission from IOS Press. 
16 
 
[45]  Aguayo LG , Castro P , Mariqueo T , Munoz B , Xiong W , Zhang L , 
Lovinger DM , Homanics GE ((2014) ) Altered sedative effects of 
ethanol in mice with alpha1 glycine receptor subunits that are 
insensitive to Gbetagamma modulation. Neuropsychopharmacology 
39:, 2538–2548. 
[46]  Mariqueo TA , Agurto A , Munoz B , San Martin L , Coronado C , 
Fernandez-Perez EJ , Murath P , Sanchez A , Homanics GE , Aguayo LG 
((2014) ) Effects of ethanol on glycinergic synaptic currents in mouse 
spinal cord neurons. J Neurophysiol 111:, 1940–1948. 
[47]  De Paillerets C , Gallay J , Alfsen A ((1984) ) Effect of cholesterol and 
protein content on membrane fluidity and 3 beta-hydroxysteroid 
dehydrogenase activity in mitochondrial inner membranes of bovine 
adrenal cortex. Biochim Biophys Acta 772:, 183–191. 
[48]  Kawahara M , Kuroda Y ((2001) ) Intracellular calcium changes in 
neuronal cells induced by Alzheimer’s beta-amyloid protein are blocked 
by estradiol and cholesterol. Cell Mol Neurobiol 21:, 1–13. 
[49]  Chi EY , Frey SL , Lee KY ((2007) ) Ganglioside G(M1)-mediated 
amyloid-beta fibrillogenesis and membrane disruption. Biochemistry 
46:, 1913–1924. 
[50]  Forman MS , Mufson EJ , Leurgans S , Pratico D , Joyce S , Leight S , 
Lee VM , Trojanowski JQ ((2007) ) Cortical biochemistry in MCI and 
Alzheimer disease: Lack of correlation with clinical diagnosis. Neurology 
68:, 757–763. 
 
  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Alzheimer’s Disease, Vol 53, No. 1 (2016): pg. 197-207. DOI. This article is © IOS Press and permission has been 
granted for this version to appear in e-Publications@Marquette. IOS Press does not grant permission for this article to be 
further copied/distributed or hosted elsewhere without the express permission from IOS Press. 
17 
 
Figures and Tables 
Fig. 1. Treatment with trypsin decreased NMDARs in hippocampal neurons. A) 
Microphotograph shows NMDAR (NR2B, red) in neuronal primary processes of cultures 
treated without or with trypsin (0.00025%, 30  min). B) Quantification of NMDAR 
puncta number shows a decrease in trypsin-treated neurons (0.00025%, 30 min) 
versus control (not treated). C) Western blot showing the levels of NR2B in control and 
trypsin-treated neurons (0.00025%, 30 min). α-tubulin was used as a loading control. 
D) Quantification of NR2B levels from the western blot in control and treated neurons. 
E) Representative evoked currents using NMDA (100 μM) and NMDA plus D-AP5 (100 
μM) in control neurons and pre-treatment with trypsin 0.00025% for 30 min. Black bar 
represents the time of perfusion. F) Plot of current density (pA/pF) in control and 
trypsin pre-treated neurons showing the current decrease in trypsin-treated neurons. 
G) The graph shows the capacitance (pF) in control and trypsin-treated cells. 
**p < 0.01; ***p < 0.001. 
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Fig. 2. Trypsin treatment decreased NMDARs and increased Aβ association in 
hippocampal neurons. A) Immunofluorescence microphotograph showing the 
association of Aβ-FAM (1 μM, 1 h) to hippocampal neurons pre-treated with or without 
trypsin (0.00025%, 30 min). NMDA receptor is shown in red (NR2B subunit), Aβ-FAM 
in green and MAP2 in blue. Scale bar represents 20 μm. B) Representative images of 
neuronal primary processes (10 μm) showing the levels of NMDAR (red) and the 
association of Aβ-FAM (green, 1 h, 1 μM) in control and trypsin pre-treated 
(0.00025%, 30 min) neurons. The panel at the right displays a zoom of the dendrite. 
C) Plot shows the quantification of Aβ-FAM cluster size ( μm). D) Graph illustrates the 
relationship between the number and size (nm) of Aβ-FAM clusters in control and 
treated neurons. **p < 0.01. 
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Fig. 3. NMDARs affect Aβ association in hippocampal neurons. A) Representative 
traces of NMDA-evoked currents in control and after transfection with siRNAs geared 
towards the NMDAR (NR1 and NR2B subunits). The black bar represents the time of 
NMDA perfusion (100 μM). B) Plot showing the decrease in the amplitude of NMDA-
evoked currents for the siRNA-transfected neurons versus control. C) 
Immunofluorescence showing Aβ-FAM (green) association (1 μM, 1 h) to control and 
siRNA transfected neurons. MAP2 stained the neurons (blue) and mCherry was used as 
a control for transfection (red). The white bottom bar represents 20 μm of length. D, 
E) Plots show the Aβ-FAM puncta number and fluorescence intensity in primary 
processes (20 μm) for control and transfected neurons. *p < 0.05, **p < 0.01. 
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Fig. 4. Trypsin treatment decreased the time to perforated configuration induced by 
Aβ. A) Representative capacitative currents (5 mV) in the perforated configuration 
using Aβ (1 μM) in the pipette in HEK cells. B) Plot showing the charge transferred 
through the membrane of the cell in a time dependent manner, showing that Aβ 
perforates the membrane faster in trypsin pre-treated cells (0.00025%, 30 min) than 
in control cells without any treatments. Arrow heads (red) indicate the times of the 
recordings shown in panel A. C) Graph showing the time needed by Aβ to acquire a 
perforation configuration. The trypsin pre-treated cells had a faster perforation time. 
*p < 0.05, **p < 0.01. 
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Fig. 5. NMDAR overexpression increased Aβ-FAM clustering in HEK cells. A) The trace 
shows NMDA-evoked current in HEK cells transfected with NR1 and NR2B. B) The trace 
shows a glycine evoked current in HEK cells transfected with the alpha subunit of the 
glycine receptor (GlyRα1). C) Microphotograph showing Aβ-FAM association (1 μM, 1 h) 
to HEK cells overexpressing NMDAR (NR1/NR2B), GlyRα1 and RFP as a control for 
transfection. D) Plot showing the Aβ-FAM cluster inter-distance. E) Graph showing the 
increase in Aβ-FAM cluster size in cells that overexpress NMDAR. **p < 0.01. 
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Fig. 6. NMDAR overexpression inhibited the Aβ-induced membrane perforation. A) 
Scheme representing the perforated patch clamp configuration used in the 
experiment. Aβ is added to the patch pipette with the internal solution and the cell-
attached configuration is acquired. The recorded cells were previously transfected with 
GFP, NMDAR or GlyRα1. B) Plot showing the membrane charge transferred (fC) in 
control HEK cells and HEK cells transfected with GFP, NMDAR or GlyRα1 after 20 min in 
the presence of Aβ (1 μM). The cells that overexpressed NMDARs were resistant to Aβ. 
Na7, a peptide that blocks the amyloid pore, was used as a control for the Aβ 
perforation. **p < 0.01, ***p < 0.001. 
 
Fig. 7. “Forest effect” of membrane proteins involved in Aβ association and membrane 
perforation. A) The increase in membrane protein levels, such as NMDAR, augments 
the association of Aβ (red circles) to these proteins, decreasing the association of Aβ 
to membrane lipids and therefore the perforation induced by Aβ. B) The decrease in 
membrane proteins, i.e., NMDAR, results in an increase in Aβ association to the lipids 
of the plasma membrane, thus increasing the perforation induced by Aβ. 
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